Swiss firm Lonza to help produce anti-Covid nasal spray in the US
As part of its agreement with American company Altimmune, Lonza will allocate a dedicated manufacturing facility for AdCOVID nasal spray vaccine near Houston, Texas.
On Friday, Altimmune announced the specific role the Swiss company will play in the rollout of the AdCOVID nasal spray. Lonza was named as a manufacturing partner last November.
“By expanding our Lonza collaboration and commissioning our own dedicated manufacturing suite, we are building extra capacity and redundancy into our manufacturing to support potential late-stage clinical trials with AdCOVID and potential future commercial supply,” said Vyjayanthi Krishnan, vice president of product development at Altimmune.
AdCOVID has started phase 1 clinical trials and the results are expected in the second quarter of 2021. If successfully commercialised, AdCOVID could offer “simplicity of nasal administration, potential ease of deployment and storage, and the potential to block viral transmission”, according to Altimmune CEO Vipin Garg.
Lonza sees potential in the vaccine candidate that claims to provide immunity for a year or more with a single dose and does not need specialised freezer storage.
“Altimmune’s Covid-19 vaccine candidate could be a complete game-changer in the fight against Covid-19. Our reinforced commitment is to enable the team at Altimmune to scale-up production as needed and deliver vaccines at a global scale when ready,” said Alberto Santagostino, senior vice president for Lonza.
Swisscom finalises financing for Vodafone Italia takeover
This content was published on
Telecoms group Swisscom has taken the next step in its takeover of Vodafone Italia and secured financing for the deal, the company said on Thursday.
Switzerland commits CHF50 million to combat rural poverty worldwide
This content was published on
The Federal Council approved a contribution of CHF49.5 million ($54.1 million) for the International Fund for Agricultural Development (IFAD).
Arrests made in raid against Turkish criminal organisation
This content was published on
A cross-border raid against a Turkish criminal organisation was conducted, including property searches in cantons Aargau and Zurich.
Up to 4,000 Swiss army soldiers to protect Ukraine peace conference
This content was published on
The Federal Council has authorised deployment of army personnel for the Ukraine peace conference on the Bürgenstock in June.
This content was published on
The business association, Swissmem, reports that there are increasing signs that the bottom of the downturn will be reached this year.
This content was published on
Novartis has signed an initial deal to produce the mRNA molecules for the Covid-19 vaccine developed by German biotech firm CureVac.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.